Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Earnings Roundup: Merck, Pfizer And Amgen (Part 3)

This article was originally published in PharmAsia News

Executive Summary

Pfizer lowers overall growth guidance for emerging markets this year but remains bullish on prospects for growth as EMs become more like mature markets in reimbursement and overall health care policies. Merck meanwhile emphasized cost-cutting measures and Amgen sets its sights on Japan.

You may also be interested in...



Merck Slims R&D Spend, Homes In On Best Assets Like Lambrolizumab

Merck advises that R&D spend for 2013 will be a lower than 2012 as it absorbs a hit from patent expirations of major products. Company stresses that it will prioritize drugs that have potential to shake up clinical practice, like lambrolizumab in oncology and MK-8931 in Alzheimer’s disease.

Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business

Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.

Merck Teams With Lycera In Second Autoimmune Deal

The Michigan-based biotech says the latest discovery and development deal with Merck is validation of its ongoing work with the Big Pharma in the field of autoimmune diseases.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC085047

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel